Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2021-03-11 Regulatory Filings
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Update on Data Safety Review - STAR COVID-19 trial
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Evgen Pharma PLC regarding the progress of a clinical trial (STAR COVID-19). It provides an update on the Data Safety Monitoring Committee's review of patient safety and data quality. Since it is a regulatory announcement regarding company operations and clinical trial status, and does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2021-03-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' for Evgen Pharma PLC. This form is specifically used to report changes in significant share ownership (major holdings) as required by regulatory transparency rules. It details the identity of the shareholder, the date the threshold was crossed, and the resulting percentage of voting rights. This aligns perfectly with the definition of a Major Shareholding Notification.
2021-03-09 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' for Evgen Pharma PLC. This form is specifically used to report when a shareholder's interest in a company crosses a significant threshold (in this case, 3.02%). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2021-03-08 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership (Octopus Investments Nominees Limited holding 7.96% of Evgen Pharma plc). This type of regulatory disclosure regarding significant shareholding thresholds is classified as a Major Shareholding Notification.
2021-03-05 English
Director dealing
Director's Dealing Classification · 100% confidence The document is an official notification regarding a share purchase by a company executive (CFO Richard Moulson). It explicitly uses the header 'Director dealing' and follows the standard EU Market Abuse Regulation (MAR) disclosure format for PDMR (Persons Discharging Managerial Responsibilities) transactions. This aligns perfectly with the definition for 'Director's Dealing'.
2021-03-05 English
Result of General Meeting & Total Voting Rights
Regulatory Filings Classification · 98% confidence The document contains two primary components: first, a 'Result of General Meeting' which details the voting results of resolutions (DVA), and second, a 'Director's Dealing' (DIRS) section reporting share acquisitions by PDMRs (Huw Jones and Sue Foden). Given the document structure and the primary focus on the outcome of the General Meeting and the subsequent disclosure of voting rights and director transactions, it is a multi-purpose regulatory announcement. Since the document contains specific voting results and director dealing disclosures, it fits the DVA category as the primary event (Result of General Meeting) is the headline, while the director dealings are supplementary regulatory disclosures.
2021-03-03 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.